Department of Special Treatment I, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
Cancer Rep (Hoboken). 2024 Feb;7(2):e1952. doi: 10.1002/cnr2.1952. Epub 2024 Jan 22.
To investigate the risk factors for gastrointestinal perforation in metastatic colorectal cancer patients receiving bevacizumab.
We retrospectively reviewed 217 patients with metastatic colorectal cancer receiving bevacizumab to investigate the risk factors for gastrointestinal perforation. Three patients occurred intestinal perforation after receiving bevacizumab. We analyzed the clinical characteristics of three patients with intestinal perforation.
All patients receiving bevacizumab. Three of 217 patients occurred intestinal perforation after receiving bevacizumab. Patient no. 1 was 70 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab. Patient no. 2 was 59 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation after receiving bevacizumab, and recovered smoothly after symptomatic treatment. Patient no. 3 was 60 years old, female, having history of intestinal obstruction. The patient occurred intestinal perforation and ultimately died after receiving bevacizumab.
Patients with advanced colorectal cancer receiving bevacizumab are at risk of gastrointestinal perforation. The patient's age, gender and history of bowel obstruction may be associated with gastrointestinal perforation.
探讨接受贝伐珠单抗治疗的转移性结直肠癌患者发生胃肠道穿孔的危险因素。
我们回顾性分析了 217 例接受贝伐珠单抗治疗的转移性结直肠癌患者，以探讨胃肠道穿孔的危险因素。有 3 例患者在接受贝伐珠单抗治疗后发生肠穿孔。我们分析了这 3 例肠穿孔患者的临床特征。
所有接受贝伐珠单抗治疗的患者。217 例患者中有 3 例在接受贝伐珠单抗治疗后发生肠穿孔。患者 1 为 70 岁女性，有肠梗阻病史。该患者在接受贝伐珠单抗治疗后发生肠穿孔，最终死亡。患者 2 为 59 岁女性，有肠梗阻病史。该患者在接受贝伐珠单抗治疗后发生肠穿孔，经对症治疗后恢复顺利。患者 3 为 60 岁女性，有肠梗阻病史。该患者在接受贝伐珠单抗治疗后发生肠穿孔，最终死亡。
接受贝伐珠单抗治疗的晚期结直肠癌患者有发生胃肠道穿孔的风险。患者的年龄、性别和肠梗阻病史可能与胃肠道穿孔有关。
